ACSS1 and urinary bladder cancer: In addition, several crucial lipogenic enzymes including acetyl-CoA synthetase 2 (ACSS2) and ACC were overexpressed in cisplatin-resistant bladder cancer cells and treatment with ACSS2 inhibitor or ACSS2 siRNA could abate the cisplatin resistance 43.